FY2030 Earnings Estimate for RCUS Issued By HC Wainwright

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of Arcus Biosciences in a report issued on Thursday, February 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of $0.30 for the year. HC Wainwright has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 69.86%. The firm had revenue of $33.00 million for the quarter, compared to the consensus estimate of $24.94 million. During the same quarter in the prior year, the company posted ($1.03) earnings per share. The business’s revenue was down 8.3% on a year-over-year basis.

A number of other equities analysts also recently issued reports on RCUS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday, January 21st. Wells Fargo & Company set a $23.00 target price on Arcus Biosciences and gave the company an “equal weight” rating in a report on Thursday, February 12th. Bank of America upped their price target on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. The Goldman Sachs Group raised Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $16.00 to $28.00 in a research report on Monday, January 12th. Finally, Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a research note on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Arcus Biosciences Trading Down 3.7%

NYSE:RCUS opened at $19.53 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65. Arcus Biosciences has a one year low of $6.50 and a one year high of $26.40. The company has a market cap of $2.11 billion, a PE ratio of -5.92 and a beta of 0.84. The firm has a 50-day moving average of $21.60 and a 200-day moving average of $18.36.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 6,552 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $23.38, for a total transaction of $153,185.76. Following the sale, the chief financial officer owned 67,924 shares of the company’s stock, valued at $1,588,063.12. The trade was a 8.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Carolyn C. Tang sold 6,810 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $22.16, for a total value of $150,909.60. Following the sale, the general counsel owned 124,734 shares in the company, valued at approximately $2,764,105.44. This represents a 5.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 263,987 shares of company stock worth $6,025,620 in the last ninety days. Insiders own 9.60% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. purchased a new stake in Arcus Biosciences during the 4th quarter worth about $39,000. Invesco Ltd. increased its position in shares of Arcus Biosciences by 41.7% during the fourth quarter. Invesco Ltd. now owns 414,365 shares of the company’s stock valued at $9,874,000 after buying an additional 121,961 shares during the period. State of Tennessee Department of Treasury increased its position in shares of Arcus Biosciences by 34.2% during the fourth quarter. State of Tennessee Department of Treasury now owns 34,855 shares of the company’s stock valued at $831,000 after buying an additional 8,886 shares during the period. VestGen Advisors LLC purchased a new stake in shares of Arcus Biosciences in the fourth quarter worth about $647,000. Finally, Wellington Management Group LLP boosted its position in shares of Arcus Biosciences by 309.4% in the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock valued at $123,547,000 after acquiring an additional 3,918,220 shares during the period. 92.89% of the stock is currently owned by institutional investors.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.